Financial Performance - Q3 2025 total revenue reached $510.0 million[36] - Q3 2025 gross margin was 17.0%[36] - Q3 2025 operating margin was 5.7%[36] - Q3 2025 EPS was $0.28[36] - Q4 2025 revenue guidance is between $480 million and $530 million[38] - Q4 2025 EPS guidance is between $0.11 and $0.31[39] Segment Performance - Q3 2025 products revenue was $445.0 million with a gross margin of 15.1% and an operating margin of 4.9%[37] - Q3 2025 services revenue was $65.0 million with a gross margin of 30.0% and an operating margin of 11.1%[37] Strategic Growth - The company is focused on increasing market share in manufactured components and expanding its customer base[26] - The company aims to reduce the cost of ownership for customers by leveraging advanced technology and integrated solutions[27]

Financial Performance - Q3 2025 GAAP EPS was $2.16, and Core EPS was $2.34[7] - Edison International narrowed its 2025 Core EPS guidance to $5.95–6.20[5, 7] - The company reaffirmed its confidence in delivering 5–7% Core EPS growth from 2025 to 2028, projecting an EPS of $6.74–7.14 in 2028[5] - The 2025-2028 capital plan is projected to be approximately $28–29 billion[17, 26] Regulatory and Legal Developments - California Legislature passed SB 254, establishing an $18 billion fund to support IOU financial stability, funded 50/50 by customers and IOUs, with SCE's share at approximately $145 million per year starting in 2029[5, 8] - A settlement agreement was filed to recover approximately $2.0 billion out of $5.6 billion in losses related to the Woolsey fire, representing 35% cost recovery[5, 14] - The CPUC's 2025 General Rate Case (GRC) decision approved approximately 92% of the requested base revenue, amounting to ~$9.7 billion, and 91% of the requested capital investment[17] Strategic Outlook - Edison International projects a rate base CAGR of 7–8% from 2024 to 2028[17, 31] - The company anticipates approximately 1-3% annual sales growth in the near term (2025-2028), 40-50% cumulative sales growth by 2035, and nearly 100% cumulative sales growth by 2045[52, 53] - The company expects to spend approximately $500–700 million during the 2026–2028 period on SB 254 capex[47]

Third Quarter 2025 Earnings Presentation October 28, 2025 1 Forward-Looking Statements; Non-GAAP Financial Information Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-l ...

KIWETINOHK ENERGY PLAN OF ARRANGEMENT Announced October 28, 2025 Kiwetinohk Announces a Cash Sale for $24.75 Per Share under Arrangement Agreement with Cygnet Energy Ltd. Arrangement Overview Transaction Metrics Highlights include: $15.20 $24.75 Pre-review (Mar 5, 2025) Transaction Price (Oct 27, 2025) $— $10.00 $20.00 $30.00 63% Premium to pre-review share price Enterprise Value ($billions) $1.1 $0.3 Market Capitalization Net Debt 1.4B EV / 2025E Production1,2 ($/boe/d) $41,500 EV / 2025E AFFO1,2 (x) 3.5x ...

Financial Performance & Targets - Adobe reaffirms its Q4 FY2025 total revenue target to be between $6075 billion and $6125 billion[14] - Adobe reaffirms its FY2025 total revenue target to be between $2365 billion and $2370 billion[62] - The company's Digital Media segment revenue is targeted at $453 billion to $456 billion for Q4 FY2025 and $1756 billion to $1759 billion for FY2025[62] - Digital Experience segment revenue is targeted at $1495 billion to $1515 billion for Q4 FY2025 and $584 billion to $586 billion for FY2025[62] - Digital Experience subscription revenue is targeted at $1395 billion to $1410 billion for Q4 FY2025 and $539 billion to $541 billion for FY2025[62] Growth & Innovation - Adobe's AI-influenced ARR surpassed $5 billion exiting Q3FY25, up from over $35 billion exiting FY24[65] - Acrobat and Express have over 700 million monthly active users (MAU), growing 25% year-over-year[65] - Key components of GenStudio have ARR surpassing $1 billion, growing over 25% year-over-year[65] Customer Focus - Adobe is focusing on AI-powered apps for Business Professionals & Consumers, creative power for Creative Professionals, and customer experience orchestration for Marketing Professionals[19] - The company's strategy includes strategic product platform initiatives across Acrobat + Express, Firefly, Creative Cloud, AEP + Apps, and AEM + Agentic Web[21] - One Adobe deals are growing 60% year-over-year[65]

Q3 2025 Financial Performance - Revenue reached $27.3 million in Q3 2025[38] - Gross profit margin was 55% in Q3 2025[38] - New patient starts totaled 5,334 in Q3 2025[13] - Approximately 70% of new patient starts in Q3 2025 came from multiple daily injections[14] - New patient starts reimbursed through pharmacy were in the low 30s % in Q3 2025[14] Strategic Initiatives - The company launched the Color iLet in October 2024, featuring a color screen and brighter display[17] - The company launched Libre 3 Plus Integration in November 2024, which is the first insulin pump in the U S to integrate with Abbott's Freestyle Libre 3 Plus[17] - The company released Bionic Portal Update in May 2025, allowing HCPs to access real-time clinical outcomes for their patients[18] - The company has effective formulary agreements in place with all major PBMs operating in the U S as of July 2025[21] - The company received iLet Special 510(k) Clearance in September 2025 for usability improvements and a faster cartridge change process[22] Full Year 2025 Guidance - The company projects total revenue to be greater than $96.5 million for the full year 2025[25] - The company anticipates a gross margin of 54-55% for the full year 2025[25] - The company expects new patient starts through pharmacy to be 27-29% for the full year 2025[25]

Financial Performance - Total Neurocrine net product sales reached $790 million, representing a 16% quarter-over-quarter (QoQ) growth and a 28% year-over-year (YoY) growth compared to Q2 2025 and Q3 2024, respectively[11] - INGREZZA net product sales were $687 million, showing a 10% QoQ growth and a 12% YoY growth compared to Q2 2025 and Q3 2024, respectively[11] - CRENESSITY net product sales amounted to $98 million, including 540 total new patient enrollment forms[11] - The company reaffirmed INGREZZA net sales guidance at $2500 million - $2550 million for the full year 2025[11] - Cash and investments totaled approximately $2100 million as of September 30, 2025[7] Research and Development - The company initiated all Phase 3 registrational studies for osavampator (AMPA PAM) as an adjunctive therapy for the treatment of MDD in adults and direclidine (Selective M4 Agonist) for the treatment of Schizophrenia[11] - The company expects to report top-line data in Q4 2025 for the Phase 3 study of valbenazine for Dyskinetic Cerebral Palsy and the Phase 2 study of NBI-'770 (NMDA NR2B NAM) for the treatment of MDD[11] - The company plans to initiate Phase 2 studies in Q4 2025 for direclidine for Bipolar Mania and NBI-'570 (Selective Dual M1 / M4 Agonist) for Schizophrenia[11] Commercial Strategy - The company plans to expand INGREZZA and CRENESSITY sales teams in Q4 2025, with completion expected by the end of Q1 2026, to maximize commercial momentum[11] - CRENESSITY has achieved approximately 80% reimbursement coverage for dispensed scripts[11] Pipeline Development - The company has a pipeline of 12 programs, including the first biologic program NBIP-'1435[8] - The company is advancing additional internally developed pre-clinical programs, including biologics, into first-in-human studies[11]

Varonis Overview Q3 2025 Safe Harbor Statement This presentation has been prepared by Varonis Systems, Inc. (the "Company") solely for informational purposes. It is not, and should not be assumed to be, complete. This presentation is not an offer to sell securities, nor is it a solicitation of an offer to buy securities. This presentation is not directed at, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other juris ...

Landstar System, Inc. Earnings Conference Call 3Q 2025 Date Management also believes that it is appropriate to present each of the financial measures that may be deemed a non-GAAP financial measure, as referred to above, for the following reasons: (1) disclosure of these matters will allow investors to better understand the underlying trends in the Company's financial condition and results of operations; (2) this information will facilitate comparisons by investors of the Company's results as compared to th ...

Global Science. One Purpose. 48-week Phase 3 Clinical Trial Data from China for Telitacicept in Primary Sjögren's Disease October 28, 2025 Forward Looking Statement This presentation (the "Presentation") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. ("Vor," "Vor Bio" or the "Company"). The words "aim," "anticipate," "believe," "can," "could," "design," "enable" "estimate," "expect," "intend," "may," "ongoing," "plan," ...